Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Langley

Showing results (281-290 of 345) with videos related to

Pageof 35
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2017
2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious DiarrheaAndi L Shane, Rajal K Mody, John A Crump, et al.
Vaccine|January 12, 2011
A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illnessJ M Langley, F Aoki, B J Ward, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 2, 2017
2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious DiarrheaAndi L Shane, Rajal K Mody, John A Crump, et al.
Vaccine|June 16, 2016
Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network studyJ M Langley, D M MacDougall, B A Halperin, et al.
Vaccine|April 4, 2012
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) studyJoanne M Langley, David W Scheifele, Caroline Quach, et al.
Emerging Infectious Diseases|February 25, 2020
Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada<sup>1</sup>Joanne M Langley, Soren Gantt, Caroline Quach, et al.
Vaccine|November 26, 2011
Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous doseScott A Halperin, David Scheifele, Gaston De Serres, et al.
Human Vaccines & Immunotherapeutics|November 12, 2016
Assessing the risk of intussusception and rotavirus vaccine safety in CanadaSteven Hawken, Robin Ducharme, Laura C Rosella, et al.
Vaccine|March 29, 2017
Knowledge, attitudes, beliefs, and behaviors of university students, faculty, and staff during a meningococcal serogroup B outbreak vaccination programD M MacDougall, J M Langley, L Li, et al.
Vaccine|March 8, 2012
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulationsAmeneh Khatami, Matthew D Snape, Elizabeth Davis, et al.
Pageof 35

Showing results (281-290 of 345) with videos related to

Sort By:
Pageof 35
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 21, 2017
2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious DiarrheaAndi L Shane, Rajal K Mody, John A Crump, et al.
Vaccine|January 12, 2011
A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illnessJ M Langley, F Aoki, B J Ward, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 2, 2017
2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious DiarrheaAndi L Shane, Rajal K Mody, John A Crump, et al.
Vaccine|June 16, 2016
Rapid surveillance for health events following a mass meningococcal B vaccine program in a university setting: A Canadian Immunization Research Network studyJ M Langley, D M MacDougall, B A Halperin, et al.
Vaccine|April 4, 2012
Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) studyJoanne M Langley, David W Scheifele, Caroline Quach, et al.
Emerging Infectious Diseases|February 25, 2020
Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada<sup>1</sup>Joanne M Langley, Soren Gantt, Caroline Quach, et al.
Vaccine|November 26, 2011
Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous doseScott A Halperin, David Scheifele, Gaston De Serres, et al.
Human Vaccines & Immunotherapeutics|November 12, 2016
Assessing the risk of intussusception and rotavirus vaccine safety in CanadaSteven Hawken, Robin Ducharme, Laura C Rosella, et al.
Vaccine|March 29, 2017
Knowledge, attitudes, beliefs, and behaviors of university students, faculty, and staff during a meningococcal serogroup B outbreak vaccination programD M MacDougall, J M Langley, L Li, et al.
Vaccine|March 8, 2012
Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulationsAmeneh Khatami, Matthew D Snape, Elizabeth Davis, et al.
Pageof 35